Received Jul 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 1 | — | — |
Voice message received from SRP mailbox on 26JUN2025 at 703PM with following message verbatim: "Hi Good afternoon my name is {REDACTED} calling from REDACTED} our phone number is (REDACTED) again this is {REDACTED}from {REDACTED} our hum; low grad fever; This spontaneous report was received from other health professional and refers to a female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), dose number 1, (lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient experienced low grade fever and hives (pyrexia and urticaria). At the reporting time, the outcome of the events was unknown. The causal relationship between the events and the vaccine was not provided. Lot # is being requested and will be submitted if received.